

## Digital Gene Technologies Incorporated

[View the current Digital Gene Technologies Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/3440-Digital+Gene+Technologies+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/3440-Digital+Gene+Technologies+Incorporated.html>)

### Contact Details:

11149 N. Torrey Pines Road Suite 110

La Jolla

CA

92037

United States of America

Tel: 619 552 1400

Fax: 619 552 8625

Email:

### Recent Publications by Digital Gene Technologies Incorporated:



- [Cell culture modeling of specialized tissue: identification of genes expressed specifically by follicle-associated epithelium of Peyer's patch by expression profiling of Caco-2/Raji co-cultures.](#)  
*Peyer's patch follicle-associated epithelium (FAE) regulates intestinal...*3rd August, 2004  
Digital Gene Technologies,- Int Immunol. 2004 Jan;16(1):91-9.
- [Exploiting immune surveillance mechanisms in mucosal vaccine development.](#)  
*Historically, immune responsiveness was regarded by many as an ability to...*14th July, 2004  
Digital Gene Technologies, Inc., 11149 North Torrey Pines Road, Suite- Expert Opin Biol Ther. 2004 Mar;4(3):397-406. ([DOI Direct Link](#))
- [Peptidoglycan recognition protein expression in mouse Peyer's Patch follicle associated epithelium suggests functional specialization.](#)  
*Mammalian Peyer's Patches possess specialized epithelium, the follicle...*6th December, 2003  
Digital Gene Technologies,- Cell Immunol. 2003 Jul;224(1):8-16.
- [Open system gene expression profiling and identification of novel genes for targeted vaccine delivery.](#)  
*Ongoing development of vaccines is limited by the techniques used to...*26th September, 2003  
Digital Gene Technologies,- Expert Rev Vaccines. 2002 Jun;1(1):95-100. ([DOI Direct Link](#))
- [Multiple sclerosis: emerging opportunities for therapeutic intervention.](#)  
*Multiple sclerosis (MS) is a demyelinating disease of the central nervous...*17th June, 2003  
Department of Integrative Biology, Digital Gene Technologies, Inc, 11149- Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):17-30.
- [Catching target receptors for drug and vaccine delivery using TOGA gene expression profiling.](#)  
*Drug delivery technologies are commonly directed towards formulations to...*22nd May, 2003

Digital Gene Technologies, Inc, 11149 North Torrey Pines Road, La Jolla,- Adv Drug Deliv Rev. 2002 Nov 5;54(9):1213-23.

- [Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia.](#)

*Microglial activation is an early and common feature of almost all...* 17th January, 2003

Department of Molecular Biology, The Scripps Research Institute, La Jolla,- J Neurochem. 2002

Dec;83(6):1309-20.

## Press Releases on Digital Gene Technologies Incorporated:

<a href="#">Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results</a>	6th November, 2009	BioSpecifics Technologies Corp.	<p>-- In its September 3, 2009 edition, <i>The New England Journal of Medicine</i> published data from the pivotal CORD I Phase III clinical trial of XIAFLEX for the treatment of Dupuytren</p>
<a href="#">Life Saving Estill Medical Technologies Receives Prestigious &amp;apos;Dallas 100(TM)&amp;apos; Award</a>	6th November, 2009	Estill Medical Technologies, Inc.	<p>Award-Winning Company is Maker of The Thermal Angel Blood &amp; IV Fluid Infusion Warmer DALLAS, Nov. 6 /PRNewswire-USNewswire/ -- Estill Medical Technologies, a family-owned Texas company that</p>
<a href="#">Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement &amp; Construction of World Scale Renewable Succinic Acid Plants</a>	6th November, 2009	Myriant Technologies LLC	<p>QUINCY, Mass., Nov. 6 /PRNewswire/ -- Myriant Technologies LLC ("Myriant"), a privately-held, biotech developer and manufacturer of renewable bio-chemicals, Uhde Corporation of America and</p>
<a href="#">OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy</a>	6th November, 2009	VirtualHealth Technologies, Inc.	<p>LEXINGTON, Ky., Nov. 6 /PRNewswire-FirstCall/ -- Virtual Health Technologies, Inc. (OTC Bulletin Board: VHGI) confirmed today that the previously confirmed Letter of Intent to sell all health care</p>
<a href="#">Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call</a>	6th November, 2009	Derma Sciences, Inc.	<p>PRINCETON, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced plans to release its third quarter 2009 results</p>

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

